Geratherm Medical AG (GB:0EL9)
LSE:0EL9
0EL9 Stock Chart & Stats
€2.84
€0.08(2.35%)
At close: 4:00 PM EST
€2.84
€0.08(2.35%)
Day’s Range― - ―
52-Week Range€2.64 - €7.76
Previous CloseN/A
Volume52.00
Average Volume (3M)23.00
Market Cap
€14.86M
Enterprise Value€9.75M
Total Cash (Recent Filing)€9.61M
Total Debt (Recent Filing)€2.62M
Price to Earnings (P/E)16.4
Beta0.29
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding5,444,998
10 Day Avg. Volume26
30 Day Avg. Volume23
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.80
Price to Sales (P/S)1.05
P/FCF Ratio12.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€16.50M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a sizable equity base provide structural financial resilience. With debt reduced since 2020–2022, the company has balance-sheet flexibility to absorb cyclical earnings shocks, support working capital, fund targeted investment, or sustain dividends during short-term profit weakness.
Recent Positive Cash GenerationPositive operating and free cash flow in consecutive recent years shows the business can convert revenue to cash even amid earnings volatility. Durable cash generation supports capex, debt reduction and shareholder distributions, and provides buffer for restructuring or product investment.
Focused Medical-device PortfolioA clear product focus on body-temperature and vital-parameter monitoring, sold across consumer and professional channels, yields a durable market niche. This specialization supports stable demand, repeat-device and consumable sales, and targeted R&D, aiding competitive positioning over time.
Bears Say
Return To Losses In 2025The swing back to operating losses and negative net margin in 2025 weakens internal funding capacity and undermines sustained profitability. Persistent losses could erode investor optionality, force cost reductions or lower R&D, and impair long-term returns on the company’s capital base.
Volatile And Uneven Revenue TrendAn uneven, generally declining multi-year top line complicates planning and dilutes operating leverage. Structural revenue variability limits predictable margin recovery, raises unit-cost risk for manufacturing, and constrains the ability to scale commercial investments sustainably.
Inconsistent Cash Flow ProfileHistoric FCF volatility and the sharp 2025 decline reduce certainty for capital allocation. Even with recent positive cash, unpredictable free cash flow makes funding acquisitions, consistent dividends or cyclical investments harder without relying on the balance sheet cushion.
0EL9 FAQ
What was Geratherm Medical AG’s price range in the past 12 months?
Geratherm Medical AG lowest share price was €2.64 and its highest was €7.76 in the past 12 months.
What is Geratherm Medical AG’s market cap?
Geratherm Medical AG’s market cap is €14.86M.
When is Geratherm Medical AG’s upcoming earnings report date?
Geratherm Medical AG’s upcoming earnings report date is Aug 27, 2026 which is in 69 days.
How were Geratherm Medical AG’s earnings last quarter?
Geratherm Medical AG released its earnings results on Jun 11, 2026. The company reported -€0.12 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.12.
Is Geratherm Medical AG overvalued?
According to Wall Street analysts Geratherm Medical AG’s price is currently Overvalued.
Does Geratherm Medical AG pay dividends?
Geratherm Medical AG does not currently pay dividends.
What is Geratherm Medical AG’s EPS estimate?
Geratherm Medical AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Geratherm Medical AG have?
Geratherm Medical AG has 5,444,998 shares outstanding.
What happened to Geratherm Medical AG’s price movement after its last earnings report?
Geratherm Medical AG reported an EPS of -€0.12 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Geratherm Medical AG?
Currently, no hedge funds are holding shares in GB:0EL9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geratherm Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.37%
12-Months-Change
Fundamentals
Return on Equity
3.75%
Trailing 12-Months
Asset Growth
-8.91%
Trailing 12-Months
Company Description
Geratherm Medical AG
Geratherm Medical AG, a German-based medical technology enterprise, organizes its operations across four primary divisions: Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems. The Healthcare Diagnostic unit offers a range of items including clinical thermometers, blood pressure monitors, and various self-test diagnostic products designed for women, such as pregnancy tests, chlamydia screens, urinary tract infection indicators, diverse ovulation solutions, and pH tests. Its Respiratory segment is dedicated to the development and production of equipment primarily for diagnosing pulmonary and cardiopulmonary function. Under the LMT brand, the Medical Warming Systems division manufactures MRI-compatible incubators for premature and newborn infants. The Cardio/Stroke segment provides analytical products aimed at assessing stroke risk by detecting atrial fibrillation. The company markets its healthcare solutions via pharmacies, hospitals, and clinics, and successfully exports its merchandise to approximately 60 nations worldwide. Established in 1990, Geratherm Medical AG's headquarters are situated in Geschwenda, Germany.